CSL shares have seen a significant downturn due to recent challenges, yet analysts see potential for recovery, with a projected rebound to $275, driven by its strong foundation and global healthcare ...
CSL shares have decreased 36.54% year-to-date, impacted by a sell-off after FY25 results and guidance downgrades, though analysts see a potential 53.52% upside. Positioned for expansion with stem cell ...
Australia's CSL, which earlier this year paused plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based influenza vaccine and antivenom ...
Forget one of one: this particular BMW 3.0 CSL is, quite literally, the very first M race car, and it’s up for sale for presumably many dollars. The very first official BMW M project was the 3.0 CSL.
SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...
CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...
CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...
SYDNEY, Oct 28 (Reuters) - Australian biotech CSL (CSL.AX), opens new tab has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu ...
CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...
Hosted on MSN
Is now the time to load up on CSL shares?
The CSL Ltd (ASX: CSL) share price has suffered from a fair amount of pain this year. As the chart below shows, it's down 26% from 18 August 2025 and almost 30% in 2025 to date. The ASX healthcare ...
The US may be riddled with layoff announcements, but it isn’t the only region undergoing considerable changes in 2025. Australian biotechnology firm CSL has announced layoffs among its workforce, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback